{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:14:08Z","timestamp":1786115648627,"version":"build-2736575974"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    EGFR exon 20 insertion mutations represent a distinct subset of non\u2013small cell lung cancer (NSCLC) with limited sensitivity to earlier-generation EGFR tyrosine kinase inhibitors (TKIs). CLN081 (zipalertinib; TAS6417) is a novel covalent EGFR TKI under development with activity against EGFR exon 20 insertion variants. We report the case of a 44-year-old man with stage IVB lung adenocarcinoma harboring an EGFR exon 20 insertion mutation who received multiple lines of systemic therapy, including CLN081. After eight months of treatment with CLN081, liquid biopsy revealed the emergence of a secondary EGFR C797S mutation (p.Cys797Ser; variant allele frequency [VAF] 0.05%), concurrent with a reduction in the exon 20 insertion allele frequency from 35.1% to 0.5%, accompanied by disease progression. Although C797S-mediated resistance has been hypothesized and demonstrated in preclinical models of CLN081 exposure, this represents, to our knowledge, the first reported\n                    <jats:italic>in vivo<\/jats:italic>\n                    identification of an EGFR C797S resistance mutation following CLN081 therapy. This case provides clinically relevant insight into resistance mechanisms associated with emerging EGFR exon 20\u2013targeted therapies.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1812440","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:32Z","timestamp":1785990272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20\u2013mutant NSCLC: case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Basil","family":"Dabbah","sequence":"first","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Gillis","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber","family":"Salim","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adar","family":"Yaacov","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar","family":"Cohen","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areen","family":"Abu Remilah","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehonatan","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shaare Zedek Medical Center","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Asna","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Peled","sequence":"additional","affiliation":[{"name":"Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of EGFR exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102605","article-title":"EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies","volume":"120","author":"Bai","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108490","article-title":"Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting","volume":"204","author":"van der Wel","year":"2025","journal-title":"Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100462","article-title":"The EGFR C797S mutation confers resistance to a novel EGFR inhibitor CLN-081 to EGFR exon 20 insertion mutations","volume":"4","author":"Kagawa","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00152?url_ver=Z39.88","article-title":"Safety, tolerability, and antitumor activity of Zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00763?url_ver=Z39.88","article-title":"Zipalertinib in patients with EGFR exon 20 insertion-positive NSCLC previously treated with platinum-based chemotherapy with or without Amivantamab","volume":"43","author":"Piotrowska","year":"2025","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00107","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting C797S mutation","volume":"67","author":"Zhu","year":"2024","journal-title":"J Med Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114206","article-title":"Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer","volume":"208","author":"Park","year":"2024","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1399975","article-title":"Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"15","author":"Hu","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2025.2481392","article-title":"Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future","volume":"40","author":"Zhang","year":"2025","journal-title":"J Enzyme Inhib Med Chem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.3390\/ijms26072957","article-title":"Strategies to overcome resistance to Osimertinib in EGFR-mutated lung cancer","volume":"26","author":"Romaniello","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:24:33Z","timestamp":1785990273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":13,"alternative-id":["10.3389\/fonc.2026.1812440"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1812440","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1812440"}}